Journal of the American Chemical Society· 2026Q1
Synthesis, Evaluation, and Context for Applications of SF5-Containing [1.1.1]Bicyclopentane and [ 2 ]Staffane “Hybrid Bioisosteres”
- 0citations
- Q1SCImago
- 2026year
Short summary
Researchers developed scalable routes to SF5-substituted [1.1.1]bicyclopentanes (SF5-BCPs) and SF5-[2]staffanes (SF5-BCP-BCPs), demonstrating their utility as hybrid bioisosteres for tuning drug properties.
AI-generated from the title and abstract; the full text is not read.
Key points
- Developed scalable synthetic routes to SF5-substituted [1.1.1]bicyclopentanes (SF5-BCPs) and SF5-[2]staffanes (SF5-BCP-BCPs).
- Demonstrated these motifs can be incorporated into drug-like molecules via carboxylic acid intermediates.
- Evaluated single (SF5-Ph → SF5-BCP) and hybrid (CF3-Ph → SF5-BCP, CF3-Ph-Ph → SF5-BCP-BCP) bioisosteric replacements using in vitro ADME profiling.
- Established a suite of building blocks and confirmed compatibility with common medicinal chemistry reactions.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Bioisosteric replacements are conventionally applied as single-variable changes to a parent molecule during drug discovery campaigns. Herein, we evaluate hybrid bioisosteric replacements as strategic combinations of multiple substitutions that counterbalance the physicochemical consequences of incorporating single bioisosteres individually. In this context, we validate SF5-substituted [1.1.1]bicyclopentanes (SF5-BCPs) and SF5-[2]staffanes (SF5-BCP-BCPs) as hybrid bioisostere motifs that have not been field-tested due to lack of access to versatile building blocks. We address a key synthetic limitation by developing scalable routes to carboxylic acid-containing intermediates that facilitate incorporation of these motifs into drug-like molecules via carbonyl group manipulations. These advances enable (1) crystallographic studies that contextualize structural features of these motifs, (2) syntheses of structurally diverse pharmaceutical and agrochemical derivatives, and (3) systematic evaluation of single (SF5-Ph → SF5-BCP) and multicomponent “hybrid” bioisosteric replacements (CF3-Ph → SF5-BCP and CF3-Ph-Ph → SF5-BCP-BCP) through in vitro ADME profiling. Finally, we investigate the chemical stability profile of these novel SF5-[2]staffanes, establish an extensive suite of building blocks, and demonstrate their compatibility with reactions frequently used in medicinal chemistry. Together, the results of this extensive study position SF5-BCPs and SF5-[2]staffanes as practical hybrid bioisosteres for tuning molecular properties in drug discovery.
The authors' abstract, as published at the source. Journal of the American Chemical Society, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmaceutical Science
Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics